ALYTEducational
Weekly updateCatch-up 3 of 4 · Week 46

Catch-up 3 of 4

Evidence and team: how we know it works, and who builds it.

Schools buy on trust: that the medicine is right, that students learn and that the team will be there. This chapter shows how we learn from what students do, how a physician checks every patient we publish, the randomised study we designed with a faculty in Brazil, and who builds ALYT.

28students in our first randomised study, in paediatrics
27 yearsour Medical Director led the European Vascular Course
130+participants in our workshops at the European Vascular Course, 2025 and 2026
12,300automated tests that run on every change

In this chapter

  1. 01We learn from what students do
  2. 02A physician checks every patient we publish
  3. 03A randomised study with a faculty in Brazil
  4. 04The team
01

We learn from what students do

Evidence is also what students actually do. Every action in ALYT is recorded with its time, so we see where a student gets stuck and can fix it within days.

The guided first shift: a patient of 68 in bed with his words and the monitor on the left; on the right Dr. Amara, the supervisor, introduces him and offers four first questions.
The guided first shift: Dr. Amara at the student's side for the first patient. Sample patient.
Every action on a clockLive since July

Each question, test and treatment is stored with its time, so we see where students hesitate.

Where new students stopSeen in November

In the first pilot weeks, many new students stopped before their first impression.

A signpostLive 12 Nov

While a test result is on its way, the student sees what to do next.

The guided first shiftBuilt 15 Nov

A supervisor at the student's side for the first patient. Switched on per school.

An AI studentNext

An AI that plays every patient through the real screen and reports where it gets stuck.

02

A physician checks every patient we publish

Medicine has to be right. Every patient starts from a written teaching source and goes live only after a physician approves it.

A written sourceEvery patient

Guidelines and references behind each case, such as the 2023 Turkish guideline for brucellosis.

An automated criticBefore review

Checks each case against its source and flags what needs a physician's decision.

Clinical reviewLive since 9 Jul

Our Medical Director approves a patient before it is published.

Reviewed by the schoolOwn patients

A school's own teachers review the patients built for their students.

03

A randomised study with a faculty in Brazil

The strongest evidence is a fair comparison. Together with a faculty of medicine in Brazil we designed a randomised study in paediatrics.

Two groupsAgreed in October

28 students: half practise with ALYT, half follow the usual teaching.

Assessed at the bedsideMini-CEX

The outcome is the Mini-CEX, a standard bedside assessment, scored by a faculty member who does not know the groups.

Fifteen patientsBuilt for the module

Paediatric patients built around the module's own topics.

Data agreementSigned 29 October

A data processing agreement between the university and ALYT.

04

The team

A small team that combines a clinical teacher with 27 years of training surgeons, and a builder who ships every week.

Mel JacobsFounder and CEO

Leads the company, the product and sales.

Prof. Michael JacobsMedical Director

Vascular surgeon and founder of the European Vascular Course, which he led for 27 years.

Faculty reviewersAt partner schools

Teachers who review the patients built for their own students.

Built with AISince July

We build and test with AI agents, which is how 196 changes shipped in 20 weeks.

What comes next

This weekReview
Our Medical Director reviews the two vascular cases for the February seminar.
Late NovemberTesting
The AI student's first round: five patients, played end to end.
DecemberDecisions
The first decisions on our priced proposals.

Next week, catch-up 4 of 4: our plan for 2027.